EN DE
Watch Beijing Bohui Innovation Technology Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing Bohui Innovation Technology Co Ltd (300318) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Beijing Bohui Innovation Technology Co Ltd stock ¥0.94, price ¥4.51, that is 79.2% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000001QR4

BB Beijing Bohui Innovation Technology Co Ltd logo Thin data Nov 7, 2026

Beijing Bohui Innovation Technology Co Ltd

300318 · SHE
Very expensive, weak quality

Our calculation puts a fair price 79% below what the stock costs today.

Low debt
Mixed Growth (revenue YoY −3.2 %/yr in CNY)
Fair value ¥0.9400 · Strongly overvalued (−79.2%)
Quality 30/100
Loss-making · -10.9% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 8/100 · thin data
Thin data
Watch Beijing Bohui Innovation Technology Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥14.02 ¥3.73 Fair Value ¥0.9400 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥3.73 – ¥14.02 · fair‑value band ¥0.4900 – ¥1.40 · the ¥4.51 price screens above the ¥0.9400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.

Follow Beijing Bohui Innovation Technology Co in your weekly email

Every Wednesday you see whether Beijing Bohui Innovation Technology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China.

Show moreShow less

The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies.

It also provides molecular platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others.

In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems.

The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.

Stock analysis

Beijing Bohui Innovation Technology Co Ltd (300318) currently trades at ¥4.51, while our model-based Fair Value estimate is ¥0.9400, 79% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: ¥0.4900 (bear) to ¥1.40 (bull), the price of ¥4.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Beijing Bohui Innovation Technology Co Ltd reported revenue of 825M CNY in FY2025 versus 715M CNY in FY2021, a compound +3.6%/yr. Reported net income was −91.9M CNY in FY2025.

Key figures

Market cap 3.7B CNY (≈ $553M) Small · P/S ratio 4.67 · EPS (TTM) ¥−0.1100 · Dividend yield 0.8% · Net margin −10.9% · Return on equity −7.7% · Return on assets (EBIT) −3.0% (5-year average) · Operating margin −9.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −79%, 300318 screens richer than that median.

Fair Value models

Bear ¥0.4900 Fair Value ¥0.9400 Bull ¥1.40
Price ¥4.51 · Downside -79.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥0.4900 ¥0.9400 ¥1.40 64
NCAV (Graham) ¥0.0600 ¥0.0800 ¥0.1300 53
All 2 models by family
Multiples
EV/EBITDA ¥0.4900 ¥0.9400 ¥1.40 64
Asset-Based
NCAV (Graham) ¥0.0600 ¥0.0800 ¥0.1300 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 23
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.8% (2019) → 4.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300318 screens overvalued: fair value 79% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Beijing Bohui Innovation Technology Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −79.2% · Bottom 25%
Profitability
Return on assets −2.1% · Above median
Net margin (12 months) −10.9% · Below median
Operating margin (12 months) −9.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 1.7% · Above median
Dividend yield (12 months) 0.8% · Below median
Balance sheet
Debt / equity 0.34× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.87× · Pricier than median
P/S (12 months) 4.51× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)9 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)83 · sector 97
DIVIDEND (yield)16 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 300318
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 300318
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 300318
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 300318
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 300318
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 300318
argenx SE ARGX $927.21 $908.40 −2% vs 300318
CSL Limited CSL A$202.04 A$183.04 −9% vs 300318
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 300318
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 300318

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Bohui Innovation Technology Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing Bohui Innovation Technology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300318

Frequently asked questions

Is Beijing Bohui Innovation Technology Co Ltd (300318) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥0.9400 versus a price of ¥4.51, about 79% lower (overvalued).
What is the fair value of 300318?
Our model-based fair value for Beijing Bohui Innovation Technology Co Ltd is ¥0.9400 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥4.51.
What is the quality score of 300318?
Beijing Bohui Innovation Technology Co Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Bohui Innovation Technology Co Ltd (300318)?
Our model-based price target is the fair value of ¥0.9400 (as of Nov 7, 2026) from 2 valuation models. Cautious scenario ¥0.4900, optimistic scenario ¥1.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Bohui Innovation Technology Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.9400, about 79% lower versus a price of ¥4.51 (overvalued). Cautious scenario ¥0.4900, optimistic scenario ¥1.40. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Bohui Innovation Technology Co Ltd (300318)?
Beijing Bohui Innovation Technology Co Ltd reported trailing-twelve-month revenue of about 816M CNY (latest available figure, as of Nov 7, 2026).
Does Beijing Bohui Innovation Technology Co Ltd pay a dividend?
Beijing Bohui Innovation Technology Co Ltd currently shows a dividend yield of 0.82% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Beijing Bohui Innovation Technology Co Ltd (300318)?
Beijing Bohui Innovation Technology Co Ltd has a dividend yield of 0.8%.
What is the intrinsic value of Beijing Bohui Innovation Technology Co Ltd (300318)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Bohui Innovation Technology Co Ltd it is ¥0.9400 per share (as of Nov 7, 2026), against a price of ¥4.51. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Beijing Bohui Innovation Technology Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300318 trades above its calculated fair value: price ¥4.51, fair value ¥0.9400, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300318?
No. The price is what the market pays today (¥4.51); the fair value is what the company's own numbers justify (¥0.9400). For Beijing Bohui Innovation Technology Co Ltd the two are ¥3.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Bohui Innovation Technology Co Ltd worth?
The market values Beijing Bohui Innovation Technology Co Ltd at about 3.7B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥4.51; our models calculate a fair value of ¥0.9400 per share.
What do the bullish and bearish scenarios say about 300318?
Our models span a range for Beijing Bohui Innovation Technology Co Ltd: cautious scenario ¥0.4900, base ¥0.9400, optimistic ¥1.40 per share (as of Nov 7, 2026, price ¥4.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Bohui Innovation Technology Co Ltd (300318)?
Balance-sheet figures for Beijing Bohui Innovation Technology Co Ltd (as of Nov 7, 2026): return on equity −7.7%, debt of 0.34 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 300318 from its 52-week high?
Beijing Bohui Innovation Technology Co Ltd trades at ¥4.51, about 45% below its 52-week high of ¥8.17 and 8% above the low of ¥4.18 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.9400 is for.
Which stocks are comparable to Beijing Bohui Innovation Technology Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Bohui Innovation Technology Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥4.51, calculated fair value ¥0.9400 (−79%), Quality Score 30/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300318 calculated?
We run Beijing Bohui Innovation Technology Co Ltd through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥0.9400 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing Bohui Innovation Technology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Bohui Innovation Technology Co Ltd (300318)?
The closing price on Nov 6, 2026 was ¥4.51. Our model-based fair value is ¥0.9400, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Bohui Innovation Technology Co Ltd right now?
The price sits above even our optimistic bull case (¥1.40). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥0.4900 to ¥1.40). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Beijing Bohui Innovation Technology Co Ltd

How large is the market capitalisation of Beijing Bohui Innovation Technology Co Ltd (300318)?
The market capitalisation of Beijing Bohui Innovation Technology Co Ltd is 3.7B CNY (≈ $553M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Bohui Innovation Technology Co Ltd (300318)?
The price-to-sales ratio of Beijing Bohui Innovation Technology Co Ltd is 4.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Bohui Innovation Technology Co Ltd (300318)?
Earnings per share at Beijing Bohui Innovation Technology Co Ltd are ¥−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Bohui Innovation Technology Co Ltd (300318)?
The dividend yield of Beijing Bohui Innovation Technology Co Ltd is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Bohui Innovation Technology Co Ltd (300318)?
The net margin of Beijing Bohui Innovation Technology Co Ltd is −10.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Bohui Innovation Technology Co Ltd (300318)?
The return on equity (ROE) of Beijing Bohui Innovation Technology Co Ltd is −7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Bohui Innovation Technology Co Ltd (300318)?
On an EBIT basis the return on assets of Beijing Bohui Innovation Technology Co Ltd is −3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Bohui Innovation Technology Co Ltd (300318)?
The operating margin of Beijing Bohui Innovation Technology Co Ltd is −9.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Bohui Innovation Technology Co Ltd (300318)?
Revenue at Beijing Bohui Innovation Technology Co Ltd is growing +1.7% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Bohui Innovation Technology Co Ltd (300318)?
Earnings per share at Beijing Bohui Innovation Technology Co Ltd are growing +915% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Bohui Innovation Technology Co Ltd (300318) generate?
The free cash flow of Beijing Bohui Innovation Technology Co Ltd is −292M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Beijing Bohui Innovation Technology Co Ltd (300318) carry?
The net debt of Beijing Bohui Innovation Technology Co Ltd is 720M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Beijing Bohui Innovation Technology Co Ltd in the live analysis

One click puts Beijing Bohui Innovation Technology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.